130 related articles for article (PubMed ID: 26639429)
1. Use of computational modeling approaches in studying the binding interactions of compounds with human estrogen receptors.
Wang P; Dang L; Zhu BT
Steroids; 2016 Jan; 105():26-41. PubMed ID: 26639429
[TBL] [Abstract][Full Text] [Related]
2. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method.
van Lipzig MM; ter Laak AM; Jongejan A; Vermeulen NP; Wamelink M; Geerke D; Meerman JH
J Med Chem; 2004 Feb; 47(4):1018-30. PubMed ID: 14761204
[TBL] [Abstract][Full Text] [Related]
3. Receptor-based 3D QSAR analysis of estrogen receptor ligands--merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods.
Sippl W
J Comput Aided Mol Des; 2000 Aug; 14(6):559-72. PubMed ID: 10921772
[TBL] [Abstract][Full Text] [Related]
4. Molecular structural characteristics as determinants of estrogen receptor selectivity.
Agatonovic-Kustrin S; Turner JV; Glass BD
J Pharm Biomed Anal; 2008 Sep; 48(2):369-75. PubMed ID: 18511229
[TBL] [Abstract][Full Text] [Related]
5. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding.
Zhu BT; Han GZ; Shim JY; Wen Y; Jiang XR
Endocrinology; 2006 Sep; 147(9):4132-50. PubMed ID: 16728493
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional models of non-steroidal ligands: a comparative molecular field analysis.
Menezes IR; Leitão A; Montanari CA
Steroids; 2006 Jun; 71(6):417-28. PubMed ID: 16481019
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the molecular modeling of estrogen receptor-mediated toxicity.
Tsakovska I; Pajeva I; Alov P; Worth A
Adv Protein Chem Struct Biol; 2011; 85():217-51. PubMed ID: 21920325
[TBL] [Abstract][Full Text] [Related]
8. Semiempirical QSAR study and ligand receptor interaction of estrogens.
Pasha FA; Srivastava HK; Singh PP
Mol Divers; 2005; 9(1-3):215-20. PubMed ID: 15789567
[TBL] [Abstract][Full Text] [Related]
9. Quantitative structure-activity relationship for estrogenic flavonoids from Psoralea corylifolia.
Zhang T; Zhong S; Meng Y; Deng W; Hou L; Wang Y; Xing X; Guan T; Zhang J; Li T
J Pharm Biomed Anal; 2018 Nov; 161():129-135. PubMed ID: 30149188
[TBL] [Abstract][Full Text] [Related]
10. Ligand-based identification of environmental estrogens.
Waller CL; Oprea TI; Chae K; Park HK; Korach KS; Laws SC; Wiese TE; Kelce WR; Gray LE
Chem Res Toxicol; 1996 Dec; 9(8):1240-8. PubMed ID: 8951225
[TBL] [Abstract][Full Text] [Related]
11. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptors: selective ligands, partners, and distinctive pharmacology.
Katzenellenbogen BS; Montano MM; Ediger TR; Sun J; Ekena K; Lazennec G; Martini PG; McInerney EM; Delage-Mourroux R; Weis K; Katzenellenbogen JA
Recent Prog Horm Res; 2000; 55():163-93; discussion 194-5. PubMed ID: 11036937
[TBL] [Abstract][Full Text] [Related]
13. QSAR models for binding of estrogenic compounds to estrogen receptor alpha and beta subtypes.
Tong W; Perkins R; Xing L; Welsh WJ; Sheehan DM
Endocrinology; 1997 Sep; 138(9):4022-5. PubMed ID: 9275094
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore mapping of selective binding affinity of estrogen modulators through classical and space modeling approaches: exploration of bridged-cyclic compounds with diarylethylene linkage.
Mukherjee S; Nagar S; Mullick S; Mukherjee A; Saha A
J Chem Inf Model; 2007; 47(2):475-87. PubMed ID: 17328537
[TBL] [Abstract][Full Text] [Related]
15. Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogues of estradiol-17 beta: a 3D QSAR study.
Wiese TE; Polin LA; Palomino E; Brooks SC
J Med Chem; 1997 Oct; 40(22):3659-69. PubMed ID: 9357533
[TBL] [Abstract][Full Text] [Related]
16. What are the implications of the interaction between DDT and estrogen receptors in the body?
Jaga K
Med Hypotheses; 2000 Jan; 54(1):18-25. PubMed ID: 10791702
[TBL] [Abstract][Full Text] [Related]
17. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies.
Salum Lde B; Polikarpov I; Andricopulo AD
J Mol Graph Model; 2007 Sep; 26(2):434-42. PubMed ID: 17349808
[TBL] [Abstract][Full Text] [Related]
18. Quinoids formed from estrogens and antiestrogens.
Bolton JL; Yu L; Thatcher GR
Methods Enzymol; 2004; 378():110-23. PubMed ID: 15038960
[No Abstract] [Full Text] [Related]
19. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
20. Structure-based approach for the study of estrogen receptor binding affinity and subtype selectivity.
Salum LB; Polikarpov I; Andricopulo AD
J Chem Inf Model; 2008 Nov; 48(11):2243-53. PubMed ID: 18937440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
